Thank you, Craig. And good afternoon, everyone. This past year was marked by significant progress in our strategy. We delivered strong results, enhanced our portfolio composition, strengthened our balance sheet and increased returns to shareholders. I believe that our disciplined execution and strategic capital deployment have both positioned Rand for sustained long term growth. I want to take a moment to recognize and thank our team for their hard work and dedication in executing our strategy and helping to deliver these strong results. In the fourth quarter, total investment income rose 11% to $2.1 million, bringing full year investment income to $8.6 million, an increase of 17% from the prior year. This growth was driven by our focus on expanding our debt investment portfolio, which not only enhanced income but also improved earnings stability and predictability. Although, we will always have some portfolio risk of churn or rather that is unexpected or early repayments. Our net asset value per share increased 7% year-over-year reaching $25.31 at year end. These results reflect our commitment to our investment strategy and careful management of a $71 million portfolio. A key component of this strategy has been the ongoing shift over the past few years towards a more income generating portfolio. Debt investments now comprise 75% of our portfolio, up from 64% in 2023, contributing to improved yields and a more consistent earnings profile. We also strategically monetize select equity investments, including the sale of SciAps. We've exited our remaining publicly traded securities and received some loan repayments. These have generated approximately $27 million in cash proceeds. A portion of these funds were redeployed into approximately $14 million of income generating assets. We also took deliberate steps to fortify our financial position by reducing outstanding bank debt by $15.7 million during the year. As of year-end, we had over $24 million in available credit facilities, providing us with flexibility for future investment and growth. In line with our commitment to shareholder value, we increased our regular quarterly cash dividend by 16% in the second quarter of 2024. And total dividends declared for the year reached $5.03 per share, driven largely by realized capital gains during the year. Looking ahead, I believe that Rand's financial strength will have us well positioned to capitalize on new opportunities. With strong liquidity and a proven capital deployment strategy, we are prepared to expand our investment income even further. Additionally, we are monitoring macroeconomic trends, including potential interest rate reductions, which if they happen, could enhance portfolio performance with lower interest expenses and improved profitability. Our focus remains on creating long term value for our shareholders by prudently allocating capital and managing our portfolio effectively. As highlighted on Slide 4, our success in achieving these strategic objectives over the past few years has translating into meaningful benefits for our shareholders. Since 2021, we have steadily increased dividends with quarterly dividends that once started initially at $0.10 per quarter and now are pacing at $0.29 per quarter. Our recent fourth quarter dividend was outsized and driven in part by the successful sale of SciAps during 2024. In total, we declared $4.20 per share or approximately $10.8 million dividend in the fourth quarter. This included $0.84 per share in cash dividends and a $3.36 per share stock dividend, leading to the issuance of approximately 389,000 new shares. Following this distribution at the end of January 2025, Rand has nearly 3 million shares outstanding. We recently announced our Q1 2025 dividend, and Margaret will provide the details shortly. Our commitment to a robust balance sheet and optimized portfolio and a strategic capital deployment gives us confidence in our ability to continue delivering meaningful returns for our shareholders well into the future. Turning to Slide 5, please. You will see our portfolio's distribution between debt and equity along with the recent changes. Our portfolio now stands at a fair value of $70.8 million across 22 businesses. This reflects an 8% decline from the year end 2023, primarily driven due to the successful exits from SciAps, which I had mentioned along with the stock sales and loan repayments from other portfolio companies. While we have seen an overall strengthening in many of our portfolio companies, we remain mindful of the challenging economic and political environment and consumer spending habits, which has impacted certain business operations. We have addressed some of these challenges in our fourth quarter valuations and are hopeful about future recovery in the years ahead. In the bar chart on the bottom left, you can see that during the year our portfolio companies decreased from 30 to 22, which I previously mentioned and this was largely due to monetizing our publicly traded stock holdings. With the close of the SciAps transaction, we have made substantial progress towards our goal of a more debt focused portfolio. Currently, 75% of our investments are in debt, a target ratio which we have been striving for. The annualized weighted average yield of these debt investments including PIK interest or payment in kind was 13.8% as of December 31, 2024, an increase of 20 basis points over 2023. The remaining 25% of our portfolio is comprised of equity investments, warrants or direct equity purchase in private companies. Many of these, by the way, are legacy investments. Moving forward, it will be rare for Rand to make a direct private equity investment without a related subordinated debt component that provides an interest yielding return. This is a key focus of the company at this time. Slide 6 highlights our investment activity during the fourth quarter as well as notable transactions for the full year. During Q4, we made one new investment of $2.9 million into Mobile IV Nurses Management, LLC. This investment included a $2.5 million term loan at a 14% interest rate plus 1% PIK or payment in kind alongside a $375,000 equity investment into the company. Mobile IV nurses is a growing provider of mobile IV hydration and vitamin therapy services and we believe this investment aligns well with our focus on income generating assets with a strong upside potential from the related equity investment. Additionally, during the period, we successfully exited our investment in Nailbiter, receiving full repayment of a $2.25 million debt instruments. Looking at the full year activity, our most notable transaction was the successful sale of SciAps, which generated $13.1 million in total proceeds and a realized gain of $7.7 million. SciAps was one of our long time legacy portfolio holdings and early stage investment made over a decade ago, which ultimately contributed largely to the $4.20 per share dividend, which we declared in Q4. Additionally, we continue to refine our portfolio throughout the year '24 by selling remaining shares of ACV auctions and liquidating our holdings in publicly traded BDCs. These generated total proceeds of $8.2 million. These capital recycling efforts allowed us to reinvest strategically, deploying $13.9 million across six transactions, again, with a strong emphasis on income generating debt investments. Our ability to execute on these transactions underscores our commitment to targeted capital allocation. Turning to Slide 7. You can see the evolving diversity of our portfolio and the shift in industry allocation since the end of 2023. Notably, our exposure to professional services increased from 42% to 48%, reflecting both new investments and the performance of our existing holdings. Additionally, consumer products grew as a proportion of our portfolio and now we have representation in the health and wellness sector following our investment in Mobile IV Nurses. Meanwhile, manufacturing and software saw a relative decline in portfolio mix due to the strategic portfolio adjustments and fair value updates. With the sale of our BDC stocks, they are no longer represented in the industry composition. We continue to prioritize a balanced sector diversified portfolio. This diversification is a key pillar of our investment strategy, helping to mitigate concentration risks while allowing us to capitalize on growth opportunities across many different sectors. By maintaining a broad risk across industries, we enhanced portfolio resilience, we ensure that we can navigate economic fluctuations and hopefully drive sustainable long term returns. As of year-end, Slide 8 highlights our top five portfolio companies. These collectively represent 52% of our total portfolio. Notably, Tilson remains our largest fair value investment at $11.5 million. This accounts for 16% of our portfolio. This valuation does reflect a slight decline from the prior quarter but underscores Tilson's overall strength and strategic importance within our holdings. We have been invested in Tilson for a decade. Tilson operates in the wireless and 5G mobile data sector. They design and build telecommunications networks, utilizing fiber and wireless technologies. The company's growth trajectory has been impressive, both operationally and in terms of our investment performance. With an initial investment or cost basis of approximately $3 million, our position now reflects $8.5 million in unrealized depreciation reinforcing the long term value creation of our investment strategy. This is one of our core holdings of our legacy investments. Alongside Tilson, Seybert's and Food Service Supply have been consistent names in our top five, while Mattison and Caitec moved up and ranking this year. These companies again exemplify the diversification and strength of our portfolio and we remain confident in their continued contributions to our long term growth. With that, I'll turn it over to Margaret to review our financials in greater depth.